» Articles » PMID: 21635283

Efficacy of Penguin Cap As Scalp Cooling System for Prevention of Alopecia in Patients Undergoing Chemotherapy

Overview
Journal J Adv Nurs
Specialty Nursing
Date 2011 Jun 4
PMID 21635283
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The present study examines the efficacy of a scalp cooling system to prevent chemotherapy-induced alopecia in people with cancer.

Background: Alopecia has been established as the most distressing aspect of chemotherapy to such an extent that some patients even refrain from cytotoxic treatment.

Methods: Using a quasi-experimental approach in 2007, a total number of 63 patients aged 16-59 years (mean 35 ± 5·5 years) participated in the study and were treated with an intravenous regimen of chemotherapy drug. Thirty-one patients accepting the scalp-cooling system were compared for alopecia with 32 participants who refused it. Hair loss in the participants was evaluated by nurses using World Health Organization criteria at each cycle of chemotherapy.

Results: Using chi-square test differences between the two groups were statistically significant at cycles 2-6 (P < 0·05). Twenty-four participants (77·4%) of the study group were assessed as first and second grade of alopecia in the second cycle, whereas seven participants (22·6%) of this group exhibited third and fourth grade of alopecia. However, in the control group at the same cycle, 19 participants (61·3%) were assessed with third and fourth grade of alopecia. In the Sixth cycle 15 participants (50%) of the study group and 24 participants (75%) of the control group demonstrated third and fourth grade alopecia.

Conclusion: A penguin cap can be an effective method to avoid alopecia in patients receiving chemotherapy drugs. However, it is important to bear in mind that because of individual characteristics, liver function and drug regimens it is not successful in all cases.

Citing Articles

Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia.

Lagmay-Fuentes P, Smith A, Krus S, Lewis L, Latif A, Gagliardo T J Mark Access Health Policy. 2024; 12(3):158-168.

PMID: 39072307 PMC: 11270178. DOI: 10.3390/jmahp12030013.


Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy.

Brook T, Seetsen T, Dercksen M, van Riel A, Derleyn V, van den Bosch J Oncologist. 2024; 29(10):e1386-e1395.

PMID: 38869252 PMC: 11449096. DOI: 10.1093/oncolo/oyae116.


Patient and nursing staff perspectives on automated scalp cooling (ASC) for chemotherapy-induced alopecia in breast cancer.

Ueberroth B, Kosiorek H, Nafissi N, Ertz-Archambault N, Howland A, Haddad T Support Care Cancer. 2024; 32(7):412.

PMID: 38842732 DOI: 10.1007/s00520-024-08611-2.


Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials.

Shah V, Wikramanayake T, DelCanto G, van den Hurk C, Wu S, Lacouture M J Eur Acad Dermatol Venereol. 2017; 32(5):720-734.

PMID: 28976026 PMC: 8127610. DOI: 10.1111/jdv.14612.


Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.

Rugo H, Melin S, Voigt J Breast Cancer Res Treat. 2017; 163(2):199-205.

PMID: 28275922 PMC: 5410200. DOI: 10.1007/s10549-017-4185-9.